E. Sutherland
Director/Board Member chez KRYSTAL BIOTECH, INC.
Fortune : - $ au 31/03/2024
Profil
E.
Rand Sutherland is currently the Chief Executive Officer at Upstream Bio, Inc. He is also an Independent Director at Allakos, Inc., Krystal Biotech, Inc., and Vanqua Bio, Inc. Previously, he served as the Chief Executive Officer at Seeker Biologics, Inc. from 2022 to 2023.
He also held positions at Genzyme Corp.
as the Global Head-Medical Affairs, Translate Bio, Inc. as the President in 2021, The University of Colorado as a Professor, and National Jewish Health, Inc. as the Chief of Pulmonary & Critical Care Medicine.
Dr. Sutherland completed his undergraduate degree at Oberlin College, his doctorate at The University of Chicago, and his graduate degree at Harvard T.H.
Chan School of Public Health.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
KRYSTAL BIOTECH, INC.
-.--% | 25/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
ALLAKOS, INC.
-.--% | 01/08/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de E. Sutherland
| Sociétés | Poste | Début |
|---|---|---|
| KRYSTAL BIOTECH, INC. | Director/Board Member | 18/01/2022 |
| ALLAKOS INC. | Director/Board Member | 31/07/2023 |
Vanqua Bio, Inc.
 Vanqua Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Vanqua Bio, Inc. engages in the provision of technology services. The company was founded in 2019 and is headquartered in Chicago, IL. | Director/Board Member | 01/08/2022 |
Upstream Bio, Inc.
 Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Chief Executive Officer | 02/04/2024 |
Anciens postes connus de E. Sutherland
| Sociétés | Poste | Fin |
|---|---|---|
| Seeker Biologics, Inc. | Chief Executive Officer | 01/06/2023 |
| TRANSLATE BIO, INC. | President | 14/09/2021 |
National Jewish Health, Inc.
 National Jewish Health, Inc. Medical/Nursing ServicesHealth Services National Jewish Health, Inc. provides healthcare services. It offers personalized medicines that prevents and treats respiratory, cardiac, immune and related disorders. The company was founded in 1899 and is headquartered in Denver, CO. | Corporate Officer/Principal | - |
| The University of Colorado | Corporate Officer/Principal | - |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Formation de E. Sutherland
| Oberlin College | Undergraduate Degree |
| The University of Chicago | Doctorate Degree |
| Harvard T.H. Chan School of Public Health | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ALLAKOS INC. | Health Technology |
| KRYSTAL BIOTECH, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
National Jewish Health, Inc.
National Jewish Health, Inc. Medical/Nursing ServicesHealth Services National Jewish Health, Inc. provides healthcare services. It offers personalized medicines that prevents and treats respiratory, cardiac, immune and related disorders. The company was founded in 1899 and is headquartered in Denver, CO. | Health Services |
Vanqua Bio, Inc.
Vanqua Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Vanqua Bio, Inc. engages in the provision of technology services. The company was founded in 2019 and is headquartered in Chicago, IL. | Commercial Services |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Commercial Services |
| Seeker Biologics, Inc. |
